Prof. Dr. med. Carola Berking

Lehrstuhl für Haut- und Geschlechtskrankheiten

Response to First-Line Treatment with Immune-Checkpoint Inhibitors in Patients with Advanced Cutaneous Squamous Cell Carcinoma: A Multicenter, Retrospective Analysis from the German ADOReg Registry (2022) Haist M, Stege H, Lang BM, Tsochataridou A, Salzmann M, Mohr P, Schadendorf D, et al. Journal article Melanoma 2.0. Skin cancer as a paradigm for emerging diagnostic technologies, computational modelling and artificial intelligence (2022) Vera J, Lai X, Baur A, Erdmann M, Gupta S, Gutta C, Heinzerling L, et al. Journal article, Review article Decitabine-Mediated Upregulation of CSPG4 in Ovarian Carcinoma Cells Enables Targeting by CSPG4-Specific CAR-T Cells (2022) Harrer DC, Schenkel C, Berking C, Herr W, Abken H, Dörrie J, Schaft N Journal article Long-Term Management of Advanced Basal Cell Carcinoma: Current Challenges and Future Perspectives (2022) Heppt M, Gebhardt C, Hassel JC, Alter M, Gutzmer R, Leiter U, Berking C Journal article, Review article Soluble CD83 improves and accelerates wound healing by the induction of pro-resolving macrophages (2022) Royzman D, Peckert-Maier K, Stich L, König C, Wild A, Tauchi M, Ostalecki C, et al. Journal article Real-world clinical outcomes of pembrolizumab for advanced melanoma in the German ADOREG skin cancer registry (2022) Mohr P, Scherrer E, Alar V, Assaf C, Beissert S, Berking C, Eigentler T, et al. Conference contribution Predictors of long-term survival of stage IV melanoma patients: a multicenter DeCOG study on 539 patients from the prospective skin cancer registry ADOREG (2022) Placke JM, Mohr P, Bluhm L, Kahler K, Weichenthal M, Meier F, Garzarolli M, et al. Conference contribution Therapy Management of the first Recurrence after adjuvant Therapy in Stage III: multicenter real-world Data (2022) Lodde G, Forschner A, Hassel JC, Wulfken LM, Meier F, Mohr P, Kaehler K, et al. Conference contribution Effectiveness and Safety of Dabrafenib and Trametinib in Patients with BRAFV600 Mutated Metastatic Melanoma in the Real-World Setting - Final Results of the Non-Interventional COMBI-r Study (2022) Berking C, Livingstone E, Weichenthal M, Leiter-Stoeppke U, Remy J, Eigentler T, Mohr P, et al. Conference contribution Which patients should receive adjuvant treatment - an analysis of stage IIA-IIIA patients of the CMMR (2022) Leiter-Stoppke U, Keim U, Amaral T, Forschner A, Berking C, Gesierich A, Gutzmer R, et al. Conference contribution